Table 1.

Characteristics of patients with BKV reactivation.

						Immunosuppressive medication
Patient	Gender	Age at Tx (Years)	Donor age	HLA match	BKV viremia onset after Tx	Continual*	Switch**
1	Male	28	54	3/6	64 days	MMF, PRD	TAC → CsA
2	Male	66		2/6	122 days	MMF, PRD	TAC → CsA
3	Male	52		3/6	32 days	PRD	MMF → AZA; TAC → CsA
4	Male	68	77	4/6	94 days	MMF, PRD	TAC → CsA
5	Male	59	45	0/6	~10.24 years	MMF, PRD	TAC → CsA
6	Male	66		0/6	67 days	MMF, PRD	TAC → CsA
7	Male	65	39	6/6	~6 years	MMF, PRD	TAC → CsA

^*Therapeutics that remained constant throughout the course of BKV reactivation.

^**Alteration of therapeutic regiment upon diagnosis of BKV reactivation. Values in parenthesis indicate the average daily dose.

AZA, azathioprine; CsA, Cyclosporine A; MMF, mycophenolate mofetil; PRD, prednisolone; TAC, tacrolimus.